-+ 0.00%
-+ 0.00%
-+ 0.00%

GALMED ANNOUNCES RESULTS FROM FIRST-IN-MAN PHARMACOKINETICS STUDY OF ORAL FORMULATION OF ARAMCHOL MEGLUMINE (AM); 400MG AM INCREASES BIOAVAILABILITY BY ~500% IN COMPARISON TO ARAMCHOL FREE ACID (AA) 300MG

Reuters·05/14/2026 11:30:02

Please log in to view news